Non-vitamin K oral anticoagulants (NOACs) – including dabigatran, rivaroxaban, apixaban and edoxaban – are now recommended as the preferred alternative to warfarin for reducing the risk of stroke associated with atrial fibrillation (AFib), unless patients have moderate-to-severe mitral stenosis or a mechanical heart valve, according to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation released Jan. 28 by the ACC, American Heart Association and Heart Rhythm Society and simultaneously published in the Journal of the American College of Cardiology. The focused update includes revisions to the sections on anticoagulation, catheter ablation of AFib, management of AFib complicating acute coronary syndrome, and new sections on device detection of AFib and weight loss. Read more on ACC.org. Visit the AFib Guideline Hub on ACC.org for resources, including a Guideline Made Simple tool, an AFib Focused Update: 2014-2019 Comparison Tool, and CardioSmart patient resources. The AFib Focused Update Hub on JACC also features tools, including a slide set.